Used in the treatment of chronic kidney disease (CKD), particularly diabetic nephropathy, by inhibiting GREM1, a protein that contributes to fibrosis and impaired kidney repair. By blocking GREM1 activity, this antibody helps restore the balance of signaling pathways involved in tissue regeneration, reducing fibrosis and preserving kidney function. It is also being explored in cancer therapy due to GREM1's role in tumor progression and metastasis, especially in colorectal and renal cancers. Its application supports regenerative processes in epithelial tissues and shows potential in treating fibrotic diseases beyond the kidneys, including liver and lung fibrosis.